Skip to main content
SpringerLink
Log in

Clinical trials report

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Akkoc N, van der Linden S, Khan MA: Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy. Best Pract Res Clin Rheumatol 2006, 20:539–557.

    Article  PubMed  Google Scholar 

  2. Chen J, Liu C: Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2005, (2):CD004800.

  3. Mau W, Zeidler H, Mau R, et al.: Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year followup. J Rheumatol 1988, 15:1109–1114.

    PubMed  CAS  Google Scholar 

  4. Zochling J, van der Heijde D, Burgos-Vargas R, et al.: ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006, 65:423–432.

    Article  PubMed  CAS  Google Scholar 

  5. Van den Bosch F, Kruithof E, De Vos M, et al.: Crohn’s disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on the articular symptoms. Lancet 2000, 356:1821–1822.

    Article  PubMed  Google Scholar 

  6. Van den Bosch F, Kruithof E, Baeten D, et al.: Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000, 59:428–433.

    Article  PubMed  Google Scholar 

  7. Brandt J, Haibel H, Reddig J, et al.: Successful short term treatment of severe undifferentiated spondyloarthropathy with anti-tumor necrosis factor-alpha monoclonal antibody infliximab. J Rheumatol 2002, 29:118–122.

    PubMed  CAS  Google Scholar 

  8. Breban M, Vignon E, Claudepierre P, et al.: Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology (Oxford) 2002, 41:1280–1285.

    Article  CAS  Google Scholar 

  9. Sidiropoulos P, Kritikos HD, Siakka P, et al.: Low dose of infliximab is inadequate in most patients with spondylarthropathies. Clin Exp Rheumatol 2005, 23:513–516.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Mazen Elyan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Muhammad Asim Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Elyan, M., Khan, M.A. Clinical trials report. Curr Rheumatol Rep 9, 349–352 (2007). https://doi.org/10.1007/s11926-007-0056-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-007-0056-4

Keywords

Search

Navigation